AnTolRx reports Pfizer exercises license option for potential diabetes treatment.
AnTolRx, a private biotechnology company, announced that Pfizer has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx's Type 1 diabetes research program. The option gives Pfizer exclusive rights to pursue development of AnTolRx's lead immunotherapeutic for Type 1 diabetes. Pfizer will be responsible for any further optimization, development and potential commercialization. AnTolRx will receive an upfront payment and is eligible to receive potential milestone and royalty payments from Pfizer. AnTolRx is aiming to develop targeted antigen-specific therapies, based upon immune tolerance induction rather than broader immune suppression, for several inflammatory and autoimmune diseases.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 5, 2019|
|Previous Article:||U.S. ISM services index rebounded 3.0 points to 59.7 in February.|
|Next Article:||Treasury Action: yields rebounded.|